MedTrace Logo

Spot-Scanning Based Hypofractionated Proton Therapy for Low and Intermediate Risk Prostate Cancer

NCT03740191 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2025-05-11

No results posted yet for this study

Summary

This prospective study assess the effectiveness and safety of hypofractionated proton radiotherapy in the treatment of intermediate and low risk prostate cancer.

Conditions

  • Low Risk Prostate Cancer
  • Intermediate Risk Prostate Cancer

Interventions

OTHER

EPIC questionnaire

The EPIC questionnaire is used to evaluated the Quality of life of the patients including the sexual function.

RADIATION

kV x-ray images

After the applied daily fraction, x-ray imaging will be repeated daily to assess for intra-fraction motion of the prostate.

RADIATION

Conebeam CT

For the assessment of interfraction target and organs at risk movement. Conebeam CT as soon as it becomes available will be performed 5 x/week or at each day of proton therapy before treatment application.

Sponsors & Collaborators

  • EBG MedAustron GmbH

    lead INDUSTRY

Principal Investigators

  • Carola Lütgendorf-Caucig, MD MPH MBA · EBG MedAustron GmbH

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-07-03
Primary Completion
2025-03-14
Completion
2025-03-14

Countries

  • Austria

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03740191 on ClinicalTrials.gov